Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial is testing a new tablet called YY2201 for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumor cancer that has not improved with standard treatments or no standard treatment is available.
- You are at least 18 years old and able to give written consent.
- You are in generally good health (ECOG score 0 or 1) and expected to live at least 3 months.
- Your blood counts and organ function (kidney, liver, heart) are within certain limits.
- You have at least one tumor that can be measured on a scan.
- You have not had other cancer treatments or major surgery in the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug (WJ22096) for people with advanced solid tumors that have stopped responding to or cannot tolerate standard treatments. It may be an option if you are generally healthy enough to take part.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.
This trial is testing a new oral drug called HW221043 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.